<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409276</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 124</org_study_id>
    <secondary_id>38302</secondary_id>
    <nct_id>NCT03409276</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults</brief_title>
  <official_title>A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A,B,C,A/E) / Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV-1 Vaccines (PDPHV-201401) as a Prime-boost Regimen or Co-administered in Repeated Doses, in Healthy, HIV-1-Uninfected Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of env&#xD;
      (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein/GLA-SE HIV-1 vaccines (PDPHV-201401) as&#xD;
      a prime-boost regimen or co-administered in repeated doses, in healthy, HIV-1-uninfected&#xD;
      adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety, tolerability, and immunogenicity of env (A,B,C,A/E)/gag&#xD;
      (C) DNA and gp120 (A,B,C,A/E) protein/GLA-SE HIV-1 vaccines (PDPHV-201401) as a prime-boost&#xD;
      regimen or co-administered in repeated doses, in healthy, HIV-1-uninfected adults.&#xD;
&#xD;
      The study will be conducted in two parts (Part A and Part B).&#xD;
&#xD;
      Participants in Part A will be randomly assigned to either Group 1 (Treatment) or Group 1&#xD;
      (Control). Participants in Group 1 (Treatment) will receive the gp120 (A,B,C,A/E) protein&#xD;
      vaccine admixed with GLA-SE adjuvant on Day 0 and Month 2. Participants in Group 1 (Control)&#xD;
      will receive placebo on Day 0 and Month 2.&#xD;
&#xD;
      Researchers will evaluate study data from Part A before enrolling participants in Part B.&#xD;
&#xD;
      Participants in Part B will be enrolled in either Groups 2 or 3. Within Group 2, participants&#xD;
      will be randomly assigned to either Group 2 (Treatment) or Group 2 (Control). Participants in&#xD;
      Group 2 (Treatment) will receive the env (A,B,C,A/E)/gag (C) DNA vaccine and placebo on Day 0&#xD;
      and Months 1 and 3. At Months 6 and 8, participants will receive the gp120 (A,B,C,A/E)&#xD;
      protein vaccine admixed with GLA-SE adjuvant and a placebo vaccine. Participants in Group 2&#xD;
      (Control) will receive placebo on Day 0 and Months 1, 3, 6, and 8.&#xD;
&#xD;
      Participants in Group 3 will be randomly assigned to either Group 3 (Treatment) or Group 3&#xD;
      (Control). Participants in Group 3 (Treatment) will receive the env (A,B,C,A/E)/gag (C) DNA&#xD;
      vaccine and the gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant on Day 0 and&#xD;
      Months 1, 3, 6, and 8. Participants in Group 3 (Control) will receive placebo on Day 0 and&#xD;
      Months 1, 3, 6, and 8.&#xD;
&#xD;
      Study visits for participants in Part A will occur on Day 0, Week 2, and Months 2, 2.5, 5,&#xD;
      and 8. Study visits for participants in Part B will occur on Day 0, Week 2, and Months 1,&#xD;
      1.5, 3, 3.5, 6, 6.5, 8, 8 + 1 Week, 8.5, 11, and 14. Visits may include physical&#xD;
      examinations, blood and urine collection, HIV testing, risk reduction counseling, and&#xD;
      questionnaires. Participants in Part B may also have optional saliva, semen, cervical fluid,&#xD;
      rectal fluid, and stool sample collection.&#xD;
&#xD;
      Study staff will contact all participants 12 months after the last vaccination for follow-up&#xD;
      health monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Actual">October 22, 2020</completion_date>
  <primary_completion_date type="Actual">May 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of local injection site (including DTH) reactogenicity signs and symptoms</measure>
    <time_frame>Measured through participants' last study visit, at Month 8 to 14, depending on which part of the study participants are enrolled in</time_frame>
    <description>Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of systemic reactogenicity signs and symptoms</measure>
    <time_frame>Measured through participants' last study visit, at Month 8 to 14, depending on which part of the study participants are enrolled in</time_frame>
    <description>Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs)</measure>
    <time_frame>Measured through participants' last study visit, at Month 8 to 14, depending on which part of the study participants are enrolled in</time_frame>
    <description>AEs categorized by Medical Dictionary for Regulatory Activities (MedDRA) system organ class, MedDRA preferred term, severity, and assessed relationship to study products</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of local injection site (including DTH) reactogenicity signs and symptoms</measure>
    <time_frame>Measured through participants' last study visit, at Month 8 to 14, depending on which part of the study participants are enrolled in</time_frame>
    <description>Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of systemic reactogenicity signs and symptoms</measure>
    <time_frame>Measured through participants' last study visit, at Month 8 to 14, depending on which part of the study participants are enrolled in</time_frame>
    <description>Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events (AEs)</measure>
    <time_frame>Measured through participants' last study visit, at Month 8 to 14, depending on which part of the study participants are enrolled in</time_frame>
    <description>AEs categorized by MedDRA system organ class, MedDRA preferred term, severity, and assessed relationship to study products</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with early discontinuation of vaccinations</measure>
    <time_frame>Measured through participants' last study visit, at Month 8 to 14, depending on which part of the study participants are enrolled in</time_frame>
    <description>Tabulated by reason and treatment arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnitude of serum HIV-1 Env-specific IgG responses</measure>
    <time_frame>Measured two weeks after the last vaccination (Month 8.5)</time_frame>
    <description>Assessed by Binding Antibody Multiplex Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neutralizing antibody responses against Tier 1A, Tier 1B, and selected Tier 2 viruses</measure>
    <time_frame>Measured two weeks after the last vaccination in Part B (Month 8.5)</time_frame>
    <description>Assessed by TZM-bl assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breadth of gp70-V1V2 IgG and gp120 IgA</measure>
    <time_frame>Measured two weeks after the last vaccination in Part B (Month 8.5)</time_frame>
    <description>Assessed by Binding Antibody Multiplex Assay, and antibody-dependent cellular cytotoxicity (ADCC) activities against HIV-1 subtypes A, B, C and A/E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of HIV-1 specific CD4+ and CD8+ T-cell responses</measure>
    <time_frame>Measured two weeks after the last vaccination (Month 8.5)</time_frame>
    <description>Measured by intracellular cytokine staining (ICS)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1 (Treatment): Protein Vaccine/GLA-SE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Month 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 (Control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at Day 0 and Month 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and placebo at Day 0 and Months 1 and 3. Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant and a placebo vaccine at Months 6 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (Control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 mg of the env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Months 1, 3, 6, and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 (Control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>env (A,B,C,A/E)/gag (C) DNA Vaccine</intervention_name>
    <description>Administered by intramuscular injection in the deltoid.</description>
    <arm_group_label>Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE</arm_group_label>
    <arm_group_label>Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE</arm_group_label>
    <other_name>Polyvalent DNA (PDPHV-201401) Plasmid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>gp120 (A,B,C,A/E) Protein Vaccine</intervention_name>
    <description>Administered by intramuscular injection in the deltoid.</description>
    <arm_group_label>Group 1 (Treatment): Protein Vaccine/GLA-SE</arm_group_label>
    <arm_group_label>Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE</arm_group_label>
    <arm_group_label>Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE</arm_group_label>
    <other_name>PDPHV-201401 Recombinant Proteins gp120A, gp120B, gp120C, gp120AE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.</description>
    <arm_group_label>Group 1 (Control)</arm_group_label>
    <arm_group_label>Group 2 (Control)</arm_group_label>
    <arm_group_label>Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE</arm_group_label>
    <arm_group_label>Group 3 (Control)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GLA-SE adjuvant</intervention_name>
    <description>Administered by intramuscular injection in the deltoid.</description>
    <arm_group_label>Group 1 (Treatment): Protein Vaccine/GLA-SE</arm_group_label>
    <arm_group_label>Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE</arm_group_label>
    <arm_group_label>Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE</arm_group_label>
    <other_name>glucopyranosyl lipid adjuvant-stable emulsion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General and Demographic Criteria&#xD;
&#xD;
          -  Age of 18 to 50 years&#xD;
&#xD;
          -  Access to a participating HIV Vaccine Trials Network (HVTN) clinical research site&#xD;
             (CRS) and willingness to be followed for the planned duration of the study&#xD;
&#xD;
          -  Ability and willingness to provide informed consent&#xD;
&#xD;
          -  Assessment of understanding: volunteer demonstrates understanding of this study;&#xD;
             completes a questionnaire prior to first vaccination with verbal demonstration of&#xD;
             understanding of all questionnaire items answered incorrectly&#xD;
&#xD;
          -  Willing to be contacted 12 months after the last vaccination&#xD;
&#xD;
          -  Agrees not to enroll in another study of an investigational research agent&#xD;
&#xD;
          -  Good general health as shown by medical history, physical exam, and screening&#xD;
             laboratory tests&#xD;
&#xD;
        HIV-Related Criteria:&#xD;
&#xD;
          -  Willingness to receive HIV test results&#xD;
&#xD;
          -  Willingness to discuss HIV infection risks and amenable to HIV risk reduction&#xD;
             counseling.&#xD;
&#xD;
          -  Assessed by the clinic staff as being at &quot;low risk&quot; for HIV infection and committed to&#xD;
             maintaining behavior consistent with low risk of HIV exposure through the last&#xD;
             required protocol clinic visit.&#xD;
&#xD;
        Laboratory Inclusion Values&#xD;
&#xD;
        Hemogram/Complete Blood Count (CBC)&#xD;
&#xD;
          -  Hemoglobin greater than or equal to 11.0 g/dL for volunteers who were born female,&#xD;
             greater than or equal to 13.0 g/dL for volunteers who were born male&#xD;
&#xD;
          -  White blood cell count equal to 3,300 to 12,000 cells/mm^3&#xD;
&#xD;
          -  Total lymphocyte count greater than or equal to 800 cells/mm^3&#xD;
&#xD;
          -  Remaining differential either within institutional normal range or with site physician&#xD;
             approval&#xD;
&#xD;
          -  Platelets equal to 125,000/mm^3 to 450,000/mm^3&#xD;
&#xD;
        Chemistry&#xD;
&#xD;
          -  Chemistry panel: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and&#xD;
             alkaline phosphatase less than 1.25 times the institutional upper limit of normal;&#xD;
             creatinine less than or equal to institutional upper limit of normal.&#xD;
&#xD;
        Virology&#xD;
&#xD;
          -  Negative HIV-1 and -2 blood test: US volunteers must have a negative US Food and Drug&#xD;
             Administration (FDA)-approved enzyme immunoassay (EIA).&#xD;
&#xD;
          -  Negative Hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
          -  Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase&#xD;
             chain reaction (PCR) if the anti-HCV is positive&#xD;
&#xD;
        Urine&#xD;
&#xD;
          -  Normal urine:&#xD;
&#xD;
               -  Negative urine glucose, and&#xD;
&#xD;
               -  Negative or trace urine protein, and&#xD;
&#xD;
               -  Negative or trace urine hemoglobin (if trace hemoglobin is present on dipstick, a&#xD;
                  microscopic urinalysis with red blood cells levels within institutional normal&#xD;
                  range).&#xD;
&#xD;
        Reproductive Status&#xD;
&#xD;
          -  Volunteers who were born female: negative serum or urine beta human chorionic&#xD;
             gonadotropin (Î²-HCG) pregnancy test performed prior to vaccination on the day of&#xD;
             initial vaccination. Persons who are NOT of reproductive potential due to having&#xD;
             undergone total hysterectomy or bilateral oophorectomy (verified by medical records),&#xD;
             are not required to undergo pregnancy testing.&#xD;
&#xD;
          -  Reproductive status: A volunteer who was born female must:&#xD;
&#xD;
               -  Agree to consistently use effective contraception (see the protocol for more&#xD;
                  information) for sexual activity that could lead to pregnancy from at least 21&#xD;
                  days prior to enrollment until after the last required protocol clinic visit.&#xD;
                  Effective contraception is defined as using the following methods:&#xD;
&#xD;
               -  Condoms (male or female) with or without a spermicide,&#xD;
&#xD;
               -  Diaphragm or cervical cap with spermicide,&#xD;
&#xD;
               -  Intrauterine device (IUD),&#xD;
&#xD;
               -  Hormonal contraception, or&#xD;
&#xD;
               -  Any other contraceptive method approved by the HVTN 124 Protocol Safety Review&#xD;
                  Team (PSRT)&#xD;
&#xD;
               -  Successful vasectomy in the male partner (considered successful if a volunteer&#xD;
                  reports that a male partner has [1] documentation of azoospermia by microscopy,&#xD;
                  or [2] a vasectomy more than 2 years ago with no resultant pregnancy despite&#xD;
                  sexual activity postvasectomy);&#xD;
&#xD;
               -  Or not be of reproductive potential, such as having reached menopause (no menses&#xD;
                  for 1 year) or having undergone hysterectomy, bilateral oophorectomy, or tubal&#xD;
                  ligation;&#xD;
&#xD;
               -  Or be sexually abstinent.&#xD;
&#xD;
          -  Volunteers who were born female must also agree not to seek pregnancy through&#xD;
             alternative methods, such as artificial insemination or in vitro fertilization until&#xD;
             after the last required protocol clinic visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Blood products received within 120 days before first vaccination&#xD;
&#xD;
          -  Investigational research agents received within 30 days before first vaccination&#xD;
&#xD;
          -  Body mass index (BMI) greater than or equal to 40; or BMI greater than or equal to 35&#xD;
             with 2 or more of the following: age greater than 45, systolic blood pressure greater&#xD;
             than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, current smoker, known&#xD;
             hyperlipidemia&#xD;
&#xD;
          -  Intent to participate in another study of an investigational research agent or any&#xD;
             other study that requires non-HVTN HIV antibody testing during the planned duration of&#xD;
             the HVTN 124 study&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Active duty and reserve US military personnel&#xD;
&#xD;
        Vaccines and other Injections&#xD;
&#xD;
          -  HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received&#xD;
             control/placebo in an HIV vaccine trial, the HVTN 124 PSRT will determine eligibility&#xD;
             on a case-by-case basis.&#xD;
&#xD;
          -  Non-HIV experimental vaccine(s) received within the last 5 years in a prior vaccine&#xD;
             trial. Exceptions may be made by the HVTN 124 PSRT for vaccines that have subsequently&#xD;
             undergone licensure by the FDA. For volunteers who have received control/placebo in an&#xD;
             experimental vaccine trial, the HVTN 124 PSRT will determine eligibility on a&#xD;
             case-by-case basis. For volunteers who have received an experimental vaccine(s)&#xD;
             greater than 5 years ago, eligibility for enrollment will be determined by the HVTN&#xD;
             124 PSRT on a case-by-case basis.&#xD;
&#xD;
          -  Live attenuated vaccines received within 30 days before first vaccination or scheduled&#xD;
             within 14 days after injection (eg, measles, mumps, and rubella [MMR]; oral polio&#xD;
             vaccine [OPV]; varicella; yellow fever)&#xD;
&#xD;
          -  Any vaccines that are not live attenuated vaccines and were received within 14 days&#xD;
             prior to first vaccination (eg, tetanus, pneumococcal, Hepatitis A or B)&#xD;
&#xD;
          -  Allergy treatment with antigen injections within 30 days before first vaccination or&#xD;
             that are scheduled within 14 days after first vaccination&#xD;
&#xD;
        Immune System&#xD;
&#xD;
          -  Immunosuppressive medications received within 168 days before first vaccination (Not&#xD;
             exclusionary: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical&#xD;
             corticosteroids for mild, uncomplicated dermatitis; or [4] a single course of&#xD;
             oral/parenteral prednisone or equivalent at doses less than 60 mg/day and length of&#xD;
             therapy less than 11 days with completion at least 30 days prior to enrollment.)&#xD;
&#xD;
          -  Serious adverse reactions to vaccines or to vaccine components including history of&#xD;
             anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema,&#xD;
             and/or abdominal pain. (Not excluded from participation: a volunteer who had a&#xD;
             nonanaphylactic adverse reaction to pertussis vaccine as a child.)&#xD;
&#xD;
          -  Immunoglobulin received within 60 days before first vaccination&#xD;
&#xD;
          -  Autoimmune disease, connective tissue disease, or history of vasculitis, e.g.,&#xD;
             leukocytoclastic vasculitis, Henoch-Schonlein purpura&#xD;
&#xD;
          -  Immunodeficiency&#xD;
&#xD;
        Clinically significant medical conditions&#xD;
&#xD;
          -  Untreated or incompletely treated syphilis infection&#xD;
&#xD;
          -  Clinically significant medical condition, physical examination findings, clinically&#xD;
             significant abnormal laboratory results, or past medical history with clinically&#xD;
             significant implications for current health. A clinically significant condition or&#xD;
             process includes but is not limited to:&#xD;
&#xD;
               -  A process that would affect the immune response,&#xD;
&#xD;
               -  A process that would require medication that affects the immune response,&#xD;
&#xD;
               -  Any contraindication to repeated injections or blood draws,&#xD;
&#xD;
               -  A condition that requires active medical intervention or monitoring to avert&#xD;
                  grave danger to the volunteer's health or well-being during the study period,&#xD;
&#xD;
               -  A condition or process for which signs or symptoms could be confused with&#xD;
                  reactions to vaccine, or&#xD;
&#xD;
               -  Any condition specifically listed among the exclusion criteria below.&#xD;
&#xD;
          -  Any medical, psychiatric, occupational, or other condition that, in the judgment of&#xD;
             the investigator, would interfere with, or serve as a contraindication to, protocol&#xD;
             adherence, assessment of safety or reactogenicity, or a volunteer's ability to give&#xD;
             informed consent&#xD;
&#xD;
          -  Psychiatric condition that precludes compliance with the protocol. Specifically&#xD;
             excluded are persons with psychoses within the past 3 years, ongoing risk for suicide,&#xD;
             or history of suicide attempt or gesture within the past 3 years.&#xD;
&#xD;
          -  Current anti-tuberculosis (TB) prophylaxis or therapy&#xD;
&#xD;
          -  Asthma exclusion criteria: Asthma other than mild, well-controlled asthma. (Symptoms&#xD;
             of asthma severity as defined in the most recent National Asthma Education and&#xD;
             Prevention Program (NAEPP) Expert Panel report). Exclude a volunteer who:&#xD;
&#xD;
               -  Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or&#xD;
&#xD;
               -  Uses moderate/high dose inhaled corticosteroids, or&#xD;
&#xD;
               -  In the past year has either of the following:&#xD;
&#xD;
               -  Greater than 1 exacerbation of symptoms treated with oral/parenteral&#xD;
                  corticosteroids;&#xD;
&#xD;
               -  Needed emergency care, urgent care, hospitalization, or intubation for asthma.&#xD;
&#xD;
          -  Diabetes mellitus type 1 or type 2, including cases controlled with diet alone. (Not&#xD;
             excluded: history of isolated gestational diabetes.)&#xD;
&#xD;
          -  Thyroidectomy, or thyroid disease requiring medication during the last 12 months&#xD;
&#xD;
          -  Hypertension:&#xD;
&#xD;
               -  If a person has been found to have elevated blood pressure or hypertension during&#xD;
                  screening or previously, exclude for blood pressure that is not well controlled.&#xD;
                  Well-controlled blood pressure is defined as consistently less than or equal to&#xD;
                  140 mm Hg systolic and less than or equal to 90 mm Hg diastolic, with or without&#xD;
                  medication, with only isolated, brief instances of higher readings, which must be&#xD;
                  less than or equal to 150 mm Hg systolic and less than or equal to 100 mm Hg&#xD;
                  diastolic. For these volunteers, blood pressure must be less than or equal to 140&#xD;
                  mm Hg systolic and less than or equal to 90 mm Hg diastolic at enrollment.&#xD;
&#xD;
               -  If a person has NOT been found to have elevated blood pressure or hypertension&#xD;
                  during screening or previously, exclude for systolic blood pressure greater than&#xD;
                  or equal to 150 mm Hg at enrollment or diastolic blood pressure greater than or&#xD;
                  equal to 100 mm Hg at enrollment.&#xD;
&#xD;
          -  Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions)&#xD;
&#xD;
          -  Malignancy (Not excluded from participation: Volunteer who has had malignancy excised&#xD;
             surgically and who, in the investigator's estimation, has a reasonable assurance of&#xD;
             sustained cure, or who is unlikely to experience recurrence of malignancy during the&#xD;
             period of the study)&#xD;
&#xD;
          -  Seizure disorder: History of seizure(s) within past three years. Also exclude if&#xD;
             volunteer has used medications in order to prevent or treat seizure(s) at any time&#xD;
             within the past 3 years.&#xD;
&#xD;
          -  Asplenia: any condition resulting in the absence of a functional spleen&#xD;
&#xD;
          -  History of hereditary angioedema, acquired angioedema, or idiopathic angioedema.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Frank</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Turner Overton</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hope Clinic of the Emory Vaccine Center CRS</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Health (FH) CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-4302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Vaccines to Prevent HIV Infection CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Clinical Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Prevention CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 25, 2021</submitted>
    <submission_canceled>November 11, 2021</submission_canceled>
    <submitted>November 11, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

